Integrative Inflammation–Metabolism Indicator for Cardiovascular–Kidney–Metabolic Syndrome: Evaluating the C‐Reactive Protein–Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts
Mediators of Inflammation · 2026-01 · 2026 (1)
DOI: 10.1155/mi/8912366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 28.07.2026. Verfasst von Yupeng Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Jinan University, Shenzhen 518020, China, jnu.edu.cn. Hauptthemen laut MEDLINE: C-Reactive Protein, Metabolic Syndrome, Inflammation, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major Science and Technology Special Project of Henan Province, Shenzhen Medical Research Fund.
Abstract (Originalsprache)
Background
Inflammation plays a critical role in the onset and progression of cardiovascular–kidney–metabolic (CKM) syndrome. However, the optimal inflammatory biomarker that simultaneously reflects disease severity and predicts future progression of CKM remains unexplored.
Methods
This study utilized data from three nationally representative cohorts: National Health and Nutrition Examination Survey (NHANES), UK Biobank (UKB), and China Health and Retirement Longitudinal Study (CHARLS). In NHANES, three machine learning approaches were applied to identify the inflammatory biomarker most strongly associated with CKM stages. The association between this biomarker and CKM severity was validated in UKB and CHARLS. Its predictive value for CKM progression was examined in UKB and CHARLS with Cox proportional hazard models. Multiple sensitivity analyses were conducted to ensure the robustness of the findings.
Results
Among 15 circulating inflammatory biomarkers, the C‐reactive protein–triglyceride glucose index (CTI) was identified as the most informative indicator of advanced CKM risk. In the cross‐sectional analyses, 8959 participants from NHANES, 208,625 from UKB, and 8550 from CHARLS were included. After adjustment for potential confounders, higher CTI levels were consistently associated with advanced CKM across the three cohorts (NHANES: odds ratio [OR] = 1.35, 95% confidence interval (CI): 1.20–1.48; UKB: OR = 1.55, 95% CI: 1.46–1.64; CHARLS: OR = 1.42, 95% CI: 1.28–1.60). In longitudinal analyses including 186,753 participants from UKB and 3673 from CHARLS, elevated CTI levels predicted an increased risk of incident advanced CKM (UKB: HR = 1.22, 95% CI: 1.17–1.30; CHARLS: HR = 1.21, 95% CI: 1.01–1.46).
Conclusions
CTI emerged as the most robust inflammatory biomarker for assessing disease severity and predicting CKM progression among multiple candidates. Its reproducible associations across national cohorts support its utility for early detection and risk stratification, offering a basis to refine CKM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Jinan University, Shenzhen 518020, China, jnu.edu.cn.
- Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China, szhospital.com.
- School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China, sustc.edu.cn.
- Department of Health Management, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China,…
ORCID-Profile: Lixin Cheng, Qingshan Geng
Förderung
- National Natural Science Foundation of China
- Major Science and Technology Special Project of Henan Province
- Shenzhen Medical Research Fund
Zitieren
APA
Zeng, Y., Feng, H., Cheng, H., Wu, W., He, H., Cheng, L., & Geng, Q. (2026). Integrative Inflammation–Metabolism Indicator for Cardiovascular–Kidney–Metabolic Syndrome: Evaluating the C‐Reactive Protein–Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/8912366
Vancouver
Zeng Y, Feng H, Cheng H, Wu W, He H, Cheng L, et al. Integrative Inflammation–Metabolism Indicator for Cardiovascular–Kidney–Metabolic Syndrome: Evaluating the C‐Reactive Protein–Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/8912366
BibTeX
@article{Zeng2026,
author = {Zeng, Yupeng and Feng, Huhao and Cheng, Haiying and Wu, Weiqing and He, Hui and Cheng, Lixin and Geng, Qingshan},
title = {Integrative Inflammation–Metabolism Indicator for Cardiovascular–Kidney–Metabolic Syndrome: Evaluating the C‐Reactive Protein–Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts},
journal = {Mediators of Inflammation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/mi/8912366}
}
EUVIMED